The only well confirmed genetic risk factor for sporadic Alzheimer's disease (AD) is the possession of apolipoprotein E (APOE) epsilon4 allele. As it contributes to 40-70% of AD cases, a large proportion of genetic variance may be determined by additional loci. Our aim was to estimate how reported genetic factors (APOE, NOS3, MTHFR) interact to increase the risk for AD and combine them with env...

Alzheimer's disease (AD) is the most common type of senile dementia, which often develops in elderly or presenile individuals. As one of the pathological features of AD, amyloid β‑protein (Aβ) causes energy dysmetabolism, thereby inducing cellular damage and apoptosis. Salidroside is the main active component of the traditional Chinese medicine Rhodiola. Previous studies have demonstrated that ...

Antibodies that specifically bind to either amyloidpeptide (A ) isoform A 40 or A 42 contribute to the study of Alzheimer’s disease (AD) pathology and to the development of cerebrospinal fluid-based tests for the probable diagnosis of AD. Polyclonal rabbit anti-A antibodies possess high affinity and specificity, but their generation requires a long immunization period, and the resulting antibod...

The major characteristics of Alzheimer’s disease (AD) are amyloid plaques, consisting aggregated beta (A?) peptides, together with tau pathology (tangles, neuropil treads and dystrophic neurites surrounding the plaques), in brain. Down’s syndrome (DS) individuals at increased risk to develop AD-type pathology; most DS have developed substantial already age 40. an extra copy chromosome 21, harbo...

Abstract Background The study of sex differences in Alzheimer's disease (AD) is gaining increasing attention. Yet, few studies have examined the effect genetically determined forms AD. Here, we explored impact on AD‐related clinical and biomarker changes a population‐based cohort adults with Down syndrome, who lifetime risk over 90% to develop Method This cross‐sectional 549 syndrome. We compar...

BACKGROUND Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied during the 'preclinical' stage (pathology present with cognition intact) before severe neuronal damage occurs, or upon recognizing very mild cognitive impairment. Developing and judiciously administering such therapies will require biomarker panels to identify early AD pathology, classify disease stage, m...

Down syndrome (DS) is one of the most common genetic causes of intellectual disability and is characterized by a number of behavioral as well as cognitive symptoms. Many of the neuropathological features of early-onset Alzheimer's disease (AD) including senile plaques and neurofibrillary tangles (NFTs) are also present in people with DS as a result of triplication of the amyloid precursor gene ...

Tumor promotion associated with increased dietary fat may be inhibited by reduction in total caloric intake. This hypothesis was tested in rats given either 7,12-dimethylbenz(a)anthracene to induce mammary tumors or 1,2-dimethylhydrazine to induce colon tumors. One week after dosage with either carcinogen, the rats were fed semipurified diets that provided 4% fat with ad libitum calories or 13....

Tumor promotion associated with increased dietary fat may be inhib ited by reduction in total caloric intake. This hypothesis was tested in rats given either 7,12-dimethylbenz(fl)anthracene to induce mammary tumors or 1,2-dimethylhydrazine to induce colon tumors. One week after dosage with either carcinogen, the rats were fed semipurified diets that provided 4% fat with ad libitum calories or 1...

OBJECTIVES To investigate the ability of cerebrospinal fluid (CSF) and plasma measures to discriminate early-stage Alzheimer disease (AD) (defined by clinical criteria and presence/absence of brain amyloid) from nondemented aging and to assess whether these biomarkers can predict future dementia in cognitively normal individuals. DESIGN Evaluation of CSF beta-amyloid(40) (Abeta(40)), Abeta(42...